ANNX Annexon Biosciences: Accounting Value per Share

Annexon, Inc. (ANNX) - corporate logo

This chart illustrating the price evolution of Annexon, Inc. (ANNX) highlights growth potential driven by high demand for autoimmune nervous system pathology therapies. The current figure is 1.07. The business's success relies on a team of leading experts in complement mechanisms, motivated by bonuses and scientific freedom. However, risks are associated with dependence on Asian raw materials and the complexities of international patenting.

Annexon Biosciences (ANNX) Equity per Share: for the period 07/04/2022 - 10/27/2026

annexonbio.com - analytical breakdowns and key metrics (ANNX)

- price and consensus price forecast:
Price Chart Annexon Inc.|ANNX - Broker Consensus Forecast
- market capitalization data:
Market Valuation Annexon Biosciences|ANNX - Business Value
- book capitalization data:
Net Assets per Single Share Annexon|ANNX - Accounting Capitalization|Market Capitalization to Book Value Ratio annexonbio.com|ANNX - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Annexon, Inc.|ANNX - Long-Term Debt to Capital|Short-Term Debt to Equity Annexon|ANNX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Annexon Biosciences
Fundamental company valuation:Annexon Inc., ANNX
Manufactured products of Annexon

An investment audit of the issuer requires an analysis of net assets, defined as the difference between total assets and liabilities divided by the number of shares outstanding. For Annexon, Inc. (ANNX), the book value per share curve reflects the capitalization of intellectual property and patents for C1q inhibition, allowing for an assessment of the company's actual tangible asset base against the backdrop of its scientific and technological leadership.

Competitors of Annexon, Inc. (ANNX)

Biogen Corp (BIIB) - Net Assets per Single Share|Neurocrine Corp (NBIX) - Equity per Share|Accounting Value per Share Regencell Bioscience|AXSM (axsome.com) - Equity per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|Trevi Corp (TRVI) - Net Asset Value per Share|PRAX (Praxis Precision Medicines) - Book Value per Share|Book Value per Share AVXL|Net Assets per Single Share CeriBell CBLL|Equity per Share PRTA (Prothena Corporation)|ALEC - Net Assets per Single Share|Equity per Share Omeros Corp OMER|NGNE (Neurogene Inc.) - Book Value per Share|acimmune.com (ACIU) - Net Asset Value per Share|Accounting Value per Share Voyager Therapeutics, Inc.|NMRA (Neumora) - Equity per Share|Net Assets per Single Share SCLX (Scilex Holding Co.)|Net Asset Value per Share TVGN|Net Assets per Single Share Alpha Cognition ACOG|Equity per Share Cognition Therapeutics Inc. CGTX|Accounting Value per Share Inhibikase Therapeutics, Inc.|Accounting Value of a Share Cassava Sciences Inc SAVA|Book Value per Share ASRT (Assertio Therapeutics)|COYA: Net Assets per Share|Net Assets per Single Share vistagen.com|Ovid Therapeutics (OVID) - Equity per Share|Book Value per Share ABOS|Accounting Value per Share CervoMed, Inc. (CRVO)|ATHE (Alterity Therapeutics) - Accounting Value per Share|Net Assets per Share clene.com (CLNN)|Book Value per Share PEPG (PepGen)|Jupiter Neurosciences, Inc. - Book Value per Share|Relmada Therapeutics, Inc. (RLMD) - Net Assets per Single Share|ANVS: Equity per Share|Net Assets per Single Share gracetx.com|Equity per Share Firefly Neuro|Accounting Value per Share ANEW Medical (KLTO)|Equity per Share NRSN|Net Assets per Single Share Reviva Pharmaceuticals Holdings, Inc. RVPH|Equity per Share metaviatx.com (MTVA)|NRXS: Book Value per Share|HSDT - Net Asset Value per Share|Passage Bio Corp - Accounting Value per Share|NEUP: Book Value per Share|Net Assets per Single Share Minerva Neurosciences, Inc. NERV|ATHA (Athira Pharma Inc) - Accounting Value of a Share|Net Assets per Single Share ADXN (Addex Therapeutics, Ltd.)|Net Asset Value per Share Alzamend|Book Value per Share CYCN|Book Value per Share PTIX (protagenic.com)|KTTA - Net Assets per Single Share|Cortigent Inc - Equity per Share|Avenue Therapeutics, Inc (ATXI) - Net Assets per Single Share|BCLI - Equity per Share|Book Value per Share CARA|Net Asset Value per Share chromocell.com|Accounting Value per Share Eliem Therapeutics, Inc. (ELYM)|Equity per Share ITCI|Longboard Pharma - Net Assets per Single Share|Net Asset Value per Share MRNS (Marinus Pharma)|NKGN - Net Assets per Single Share|NRBO - Equity per Share|Accounting Value per Share Sage Therapeutics (SAGE)|SNPX - Accounting Value of a Share|Trevena, Inc - Book Value per Share|VIGL (Vigil Neuroscience, Inc.) - Net Assets per Share|Net Assets per Single Share Anew Medical (WENA)|Equity per Share cerevel.com